Zanidatamab Biliary Cancer Therapy: Advancing T...

By HEOR Staff Writer

April 23, 2026

Zanidatamab biliary cancer therapy has been recommended by NICE for routine use in the NHS to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who have received at least one prior line of systemic th...
100% Tariffs Impacting Pharmaceutical Manufacturing and National Security
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strat...
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...